RT Journal Article
T1 Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers.
A1 Leon-Gonzalez, Antonio J
A1 Jimenez-Vacas, Juan M
A1 Fuentes-Fayos, Antonio C
A1 Sarmento-Cabral, Andre
A1 Herrera-Martinez, Aura D
A1 Gahete, Manuel D
A1 Luque, Raul M
K1 Cancer
K1 Insulin
K1 Metabolic syndrome
K1 Metformin
K1 Statins
AB Metabolic syndrome is associated with chronic diseases, including type 2 diabetes, cardiovascular diseases, and cancer. This review summarizes the current evidence on the antitumor effects of some relevant drugs currently used to manage metabolic-related pathologies (i.e. insulin and its analogs, metformin, statins, etc.) in endocrine-related cancers including breast cancer, prostate cancer, pituitary cancer, ovarian cancer, and neuroendocrine neoplasms. Although current evidence does not provide a clear antitumor role of several of these drugs, metformin seems to be a promising chemopreventive and adjuvant agent in cancer management, modulating tumor cell metabolism and microenvironment, through both AMP-activated protein kinase-dependent and -independent mechanisms. Moreover, its combination with statins might represent a promising therapeutic strategy to tackle the progression of endocrine-related tumors. However, further studies are needed to endorse the clinical relevance of these drugs as adjuvants for cancer chemotherapy.
PB Elsevier
YR 2021
FD 2021-07-23
LK http://hdl.handle.net/10668/18263
UL http://hdl.handle.net/10668/18263
LA en
NO León-González AJ, Jiménez-Vacas JM, Fuentes-Fayos AC, Sarmento-Cabral A, Herrera-Martínez AD, Gahete MD, et al. Role of metformin and other metabolic drugs in the prevention and therapy of endocrine-related cancers. Curr Opin Pharmacol. 2021 Oct;60:17-26
NO This work was funded by Ministerio de Ciencia e Innovación (PID2019-105564RB-I00/FPU16-05059), Instituto de Salud Carlos III (ERDF/ESF,‘Investing in your future’; PI20/01301, ISCIII-AES-2019/002525), Junta deAndalucı´a (PI-0152-2019, PI-0094-2020, PI-0038/2019, RH-0084-2020,BIO-0139), University of Córdoba (Programa Operativo FEDER Andalucía: 27416), and CIBERobn. CIBER is an initiative of Instituto de SaludCarlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain
DS RISalud
RD Apr 12, 2025